Navigation Links
Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations
Date:5/29/2015

LONDON, May 29, 2015 /PRNewswire/ --

Asthma treatment could see significant step forward aspersonalized treatments enter arena, says  GBI Research.

Despite generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), the global market for asthma treatment is set to witness moderate growth by the end of the decade.  

New analysis from business intelligence provider GBI Research Asthma Therapeutics Market to 2020 forecasts the asthma therapeutics market to grow marginally across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%.

For a complimentary sample of this research, please visit the GBI Research website.

The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.

Associate Analyst Fiona Chisholm: "Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.

"Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication."

Click here to find out how this analysis could benefit your business.

Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion. 

Three Key Findings:

  • The US will remain leading market, growing to an estimated $14 billion by 2020
  • Generic erosion of branded products has been limited by regulatory hurdles and the difficulties inherent in trying to produce a bioequivalent Inhaled Corticosteroid/Long-Acting Beta Agonist (ICS/LABA) combination drug and inhaler device
  • The UK's prevalent population for asthma will grow to 9.1 million by 2020, keeping it the highest among the five major European markets

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.

For more information, please contact GBI Research on: +44-1204-543-533

For the full range of market-leading analysis on the pharmaceutical industry, visit GBI Research's report store.

Follow GBI Research online for the latest healthcare industry updates:

Facebook  |LinkedIn  |Twitter



'/>"/>
SOURCE GBI Research
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Caris Life Sciences Vice Chairman Dr. Jonathan Knowles to Receive Personalized Medicine World Conference UK 2015 Luminary Award
2. Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024
3. Meso Scale Discovery Launches Its New U-PLEX® Platform for Personalized Immunoassay Multiplexing
4. Immunes CEO To Present on Personalized Medicine at the 2014 NY/ NJ CEO Biotech Conference
5. Health Canada approves first near-patient DNA test for personalized medicine
6. Spartan Bioscience Announces New Clinical Study Examining Personalized Testing and Treatment for Heart Attack Patients
7. International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO
8. 6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing
9. First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics
10. Geisinger and Indivumed Partner for Personalized Medicine Initiative
11. Increasing Focus on Customization of Healthcare Drives the Market for Personalized Medicine, According to a Soon to be Released Report by Global Industry Analysts, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... (PRWEB) , ... July 17, ... ... of technology-enabled clinical trial solutions, today announced safety software company AB Cube ... the eHealth Solutions business segment to advance technology innovation across life sciences ...
(Date:7/17/2017)... , ... July 17, 2017 , ... ... characterized by a wide range of overlapping clinical features. The advancement of targeted ... the field of NDD research and testing. , However, designing a custom ...
(Date:7/17/2017)... ... July 17, 2017 , ... Co-Diagnostics, Inc. ... and intends both to manufacture and sell reagents used for diagnostic tests, has ... , Headquartered in Sandy, Utah, Co-Diagnostics’ intellectual property and technologies are protected by ...
(Date:7/16/2017)... (PRWEB) , ... July 16, 2017 , ... ... equipment and analytical instruments announced the launch of its new line of Rocking ... five rocking and waving shaker models (both analog and digital) for laboratory applications ...
Breaking Biology Technology:
(Date:5/16/2017)...   Bridge Patient Portal , an enterprise ... EMR Systems , an electronic medical record solutions ... established a partnership to build an interface between ... Centricity™ products, including Centricity Practice Solution (CPS), Centricity ... new integrations will allow healthcare delivery networks using ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
Breaking Biology News(10 mins):